Millipore Sigma Vibrant Logo

HCKP1-11K MILLIPLEX® Human Immuno-Oncology Checkpoint Protein Panel 1 - Immuno-Oncology Multiplex Assay

HCKP1-11K
Design And Price Your Kit

Overview

Replacement Information
Replacement InformationThis kit will replace HCKPMAG-11K

Key Specifications Table

Analytes AvailableSpecies ReactivityKey ApplicationsDetection Methods
BTLA CD27 CD28 CD40 CD80/B7-1 CD86/B7-2 CTLA-4 GITR GITRL HVEM ICOS LAG-3 PD-1 PD-L1 PD-L2 TIM-3 TLR-2 HMplexLuminex xMAP
Description
Catalogue NumberHCKP1-11K
ReplacesHCKPMAG-11K
Trade Name
  • MILLIPLEX
DescriptionMILLIPLEX® Human Immuno-Oncology Checkpoint Protein Panel 1 - Immuno-Oncology Multiplex Assay
OverviewThe MILLIPLEX® Human Immuno-Oncology Checkpoint Protein Panel 1 is a 17-plex kit to be used for the simultaneous quantification of any or all of the following analytes in serum, plasma and tissue culture samples: BTLA (B- and T-lymphocyte attenuator), CD27 (Cluster of differentiation 27), CD28 (Cluster of differentiation 28), CD40 (Cluster of differentiation 40), CD80/B7-1 (Cluster of differentiation 80/B7-1), CD86/B7-2 (Cluster of differentiation 86/B7-2), CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), GITRL (Ligand for receptor TNFRSF18/AITR/GITR), GITR (Glucocorticoid-induced TNFR-related protein), HVEM (Herpesvirus entry mediator), ICOS (Inducible T-cell costimulator), LAG-3 (Lymphocyte-activation gene 3), PD-L1 (Programmed death-ligand 1), PD-L2 (Programmed death-ligand 2), PD-1 (Programmed cell death protein 1), TIM-3 (T-cell immunoglobulin and mucin-domain containing-3), TLR-2 (Toll like receptor 2).
Background InformationImmune checkpoint proteins are regulators of immune activation and play a key role in maintaining immune homeostasis, preventing autoimmunity, and are involved in cancer immune escape. These immune system molecules demonstrate the ability to act both as agonists (co-stimulatory checkpoint molecules) or antagonists (co-inhibitory checkpoint molecules) of immune response. Immune checkpoint inhibitor drugs targeting inhibitory immune checkpoint proteins, such as CTLA-4 and PD-L1, have demonstrated efficacy in cancer immunotherapy by improving the antitumor immune response and saving lives in the treatment of many malignancies.

Immune checkpoint proteins may express on immune cells and/or tumor cells as activating receptors or inhibitory receptors. Many immune checkpoint proteins are also expressed as soluble forms in circulation and in the tumor and tumor microenvironment and are putative biomarkers for immunotherapy in various diseases including cancer.
References
Product Information
Detection methodLuminex xMAP
ConfigurationDesign your multiplex kit by choosing available analytes within this panel.
Precision, %
  • Inter-assay: <15
  • Intra-assay: <5
Panel TypeMAGNETIC Circulating Cancer
Applications
ApplicationThe Human Immuno-Oncology Checkpoint Protein Panel 1 bead-based multiplex panel, using the Luminex xMAP technology, enables the simultaneous analysis of 17 immune checkpoint proteins in human serum, plasma and cell culture samples.
Key Applications
  • Multiplexing
Application NotesFor optimal sensitivity, use an overnight (16-18 hour) incubation. Serum and plasma samples require (recommended) a 1:2 dilution with Assay Buffer. Tissue culture supernatants may be run neat or appropriately diluted in control medium. Each well requires 25 μL of sample, standard or control.
Biological Information
SpecificityCross-reactivity between the antibodies and any of the other analytes in this panel is non-detectable or negligible.
Species Reactivity
  • Human
Analytes Available
  • BTLA
  • CD27
  • CD28
  • CD40
  • CD80/B7-1
  • CD86/B7-2
  • CTLA-4
  • GITR
  • GITRL
  • HVEM
  • ICOS
  • LAG-3
  • PD-1
  • PD-L1
  • PD-L2
  • TIM-3
  • TLR-2
Cross ReactivityCross-reactivity between the antibodies and any of the other analytes in this panel is non-detectable or negligible.
Accuracy
  • BTLA: 95%
  • CD27: 96%
  • CD28: 95%
  • CD40: 97%
  • CD80/B7-1: 96%
  • CD86/B7-2: 98%
  • CTLA-4: 95%
  • GITR: 90%
  • GITRL: 103%
  • HVEM: 98%
  • ICOS: 100%
  • LAG-3: 97%
  • PD-1: 97%
  • PD-L1: 97%
  • PD-L2: 102%
  • TIM-3: 98%
  • TLR-2: 95%
Physicochemical Information
Sensitivity
  • (minDC+ 2SD)
  • BTLA: 43.8 pg/mL
  • CD27: 24.1 pg/mL
  • CD28: 84.5 pg/mL
  • CD40: 4.3 pg/mL
  • CD80/B7-1: 11.2 pg/mL
  • CD86/B7-2: 86.1 pg/mL
  • CTLA-4: 9.3 pg/mL
  • GITR: 18.8 pg/mL
  • GITRL: 20.5 pg/mL
  • HVEM: 0.8 pg/mL
  • ICOS: 55.6 pg/mL
  • LAG-3: 66.0 pg/mL
  • PD-1: 13.7 pg/mL
  • PD-L1: 1.3 pg/mL
  • PD-L2: 46.6 pg/mL
  • TIM-3: 1.5 pg/mL
  • TLR-2: 24.1 pg/mL
Standard Curve Range
  • BTLA: 49 – 200,000 pg/mL
  • CD27: 24 – 100,000 pg/mL
  • CD28: 244 – 1,000,000 pg/mL
  • CD40: 5 – 20,000 pg/mL
  • CD80/B7-1: 12 – 50,000 pg/mL
  • CD86/B7-2: 73 – 300,000 pg/mL
  • CTLA-4: 12 – 50,000 pg/mL
  • GITR: 5 – 20,000 pg/mL
  • GITRL: 24 – 100,000 pg/mL
  • HVEM: 2 – 10,000 pg/mL
  • ICOS: 49 – 200,000 pg/mL
  • LAG-3: 122 – 500,000 pg/mL
  • PD-1: 24 – 100,000 pg/mL
  • PD-L1: 5 – 20,000 pg/mL
  • PD-L2: 49 – 200,000 pg/mL
  • TIM-3: 5 – 20,000 pg/mL
  • TLR-2: 73 – 300,000 pg/mL
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Usage Statement
  • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Storage and Shipping Information
Storage ConditionsRecommended storage for kit components is 2 - 8°C.
Packaging Information
Material Size96-well plate
Material Package96 well plate
Transport Information
Supplemental Information
Specifications